Immune-Oncology

Genmab and Bolt Biotherapeutics have entered into an oncology research and development collaboration. Together, the companies will evaluate Genmab antibodies and bispecific antibody engineering technologies in combination with Bolt’s proprietary Boltbody immune-stimulating antibody conjugate (ISAC) technology platform, with the goal of discovering and developing next-generation, immune-stimulatory, antibody-based conjugate therapeutics for the treatment of cancer. This […]

GlaxoSmithKline (GSK) will present new data from key focus areas within its oncology portfolio at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (June 4-8) and the European Hematology Association (EHA) 2021 Virtual Congress (June 9-17). The company will present new data on its approved therapies, BLENREP (belantamab mafodotin), JEMPERLI (dostarlimab) and […]

The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of cilta-cel, an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients with relapsed and/or refractory multiple myeloma. The application is supported by […]

Immunotherapy has the potential to treat a wide variety of conditions, from autoimmune disease to cancer. However, the discovery of potential antibody therapeutics against key receptor proteins remains a major challenge for the traditional immunisation approaches currently available on the market. Twist Biopharma, an arm of Twist Bioscience, was built to overcome this bottleneck by […]